Skip to main content

Table 1 Clinical, laboratory, and imaging characteristics of untreated patients with PA, SCS, or PASCS

From: Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome

 

Study diseases

P values in between-group comparisons

PA

(n = 45)

SCS

(n = 12)

PASCSa

(n = 14)

Allb

PA vs. PASCSc

SCS vs. PASCSc

PA vs. SCSc

Clinical characteristics

 Age, y

56.2 ± 1.0

62.5 ± 12.6

60.8 ± 13.1

NS

   

 Sex, female, n (%)

29 (64.4)

7 (58.3)

11 (78.6)

NS

   

 BMI, kg/m2

24.9 ± 4.2

25.2 ± 5.9

26.0 ± 4.4

NS

   

 SBP, mmHg

165.6 ± 26.1

145.6 ± 26.9

150.1 ± 27.2

<  0.05

NS

NS

NS

 DBP, mmHg

96.0 ± 13.6

80.0 ± 12.7

90.5 ± 16.4

<  0.01

NS

NS

<  0.01

Comorbidities

 Hypertension, n (%)

45 (100.0)

9 (75.0)

13 (92.9)

<  0.01

NS

NS

<  0.05

 Diabetes mellitus, n (%)

6 (14.0)

6 (50.0)

7 (50.0)

<  0.01

<  0.05

NS

NS

 Dyslipidemia, n (%)

25 (56.8)

10 (83.3)

9 (64.3)

NS

   

Laboratory characteristics

 FPG, mg/dL

103.8 ± 28.5

150.0 ± 60.7

131.6 ± 52.1

<  0.005

NS

NS

<  0.01

 HbA1c NGSP, %

5.7 ± 0.9

7.3 ± 2.2

6.5 ± 2.1

<  0.01

NS

NS

<  0.01

 TC, mg/dL

197.5 ± 42.5

208.1 ± 54.7

195.1 ± 30.4

NS

   

 TG, mg/dL

131.7 ± 88.2

148.3 ± 52.9

141.3 ± 70.3

NS

   

 HDL-C, mg/dL

55.2 ± 15.3

53.6 ± 13.9

57.0 ± 12.4

NS

   

 LDL-C, mg/dL

117.6 ± 40.3

127.2 ± 47.5

112.9 ± 23.6

NS

   

 Serum potassium, mEq/L

3.3 ± 0.7

4.0 ± 0.5

3.2 ± 0.8

<  0.01

NS

<  0.01

<  0.01

 Serum calcium, mg/dL

9.4 ± 0.4

9.5 ± 0.4

9.6 ± 0.4

NS

   

 Serum phosphorus, mg/dL

3.5 ± 0.5

3.3 ± 0.9

3.3 ± 0.4

NS

   

 UA, mg/dL

5.1 ± 1.1

4.9 ± 1.1

5.3 ± 1.3

NS

   

 Serum ALP, U/L

212.3 ± 46.3

256.8 ± 70.0

279.1 ± 105.4

<  0.005

<  0.01

NS

NS

 Erythrocyte, 106/μL

4.4 ± 0.5

4.5 ± 0.7

4.5 ± 0.3

NS

   

 Hemoglobin, g/dL

13.2 ± 1.6

13.7 ± 2.0

13.2 ± 1.4

NS

   

 Hematocrit, %

39.0 ± 4.1

41.3 ± 5.5

39.2 ± 4.1

NS

   

 Leukocyte, 103/μL

5.8 ± 1.6

6.6 ± 1.3

5.7 ± 2.0

NS

   

 Neutrophil, %

61.7 ± 7.2

64.7 ± 12.7

63.7 ± 5.3

NS

   

 Lymphocyte, %

28.9 ± 6.8

27.2 ± 11.4

28.0 ± 6.2

NS

   

 Eosinocyte, %

3.9 ± 3.4

2.4 ± 2.1

2.4 ± 1.4

NS

   

Imaging characteristics

 Laterality of tumord

       

 Left-sided, n (%)

28 (62.2)

9 (75.0)

7 (50.0)

    

 Right-sided, n (%)

14 (31.1)

3 (25.0)

5 (35.7)

    

 Bilateral, n (%)

3 (6.7)

0 (0.0)

2 (14.3)

    
  1. Values are expressed as mean ± SD or count (%)
  2. PA primary aldosteronism, SCS subclinical Cushing’s syndrome, PASCS primary aldosteronism plus subclinical Cushing’s syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c hemoglobin A1c, NGSP national glycohemoglobin standardization program, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, UA uric acid, ALP alkaline phosphatase, NS not significant, SD standard deviation
  3. aPatients with primary aldosteronism plus subclinical Cushing’s syndrome
  4. bAnalyzed according to the one-way analysis of variance
  5. cBonferroni’s correction was applied to the p values from Student’s t-test or Fisher’s exact test in multiple comparisons between two groups
  6. dDetermined by computed tomography, adrenal venous sampling, and 131I-adosterol adrenal scintigraphy
  7. A value of p <  0.05 was considered statistically significant
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us